Orbital marginal zone B-cell lymphoma of MALT: Radiotherapy results and clinical behavior

Chang-Ok Suh, Su Jung Shim, Sang wook Lee, Woo Ick Yang, Sang Yeul Lee, Jee Sook Hahn

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Purpose: To elucidate the clinical behavior and treatment outcome of low-grade primary orbital lymphoma arising from mucosa-associated lymphoid tissue (MALT). Methods and Materials: Forty-eight patients with pathologically confirmed marginal zone B-cell lymphoma of MALT were treated with radiotherapy (RT). Thirty-eight patients (79.1%) received thorough staging workup studies including bone marrow biopsy. Radiation doses ranged from 5.4 to 30.6 Gy (median, 30.6 Gy). Median follow-up period was 70 months. Results: Only 2 patients revealed extraorbital lymphoma involvement (bone marrow, skin). Forty-six of 52 eye lesions showed complete response to RT. Six lesions demonstrated a partial response and showed gradual regression during the follow-up period of 39-72 months. Three patients experienced local recurrences at 34, 48, and 52 months after RT, which seemed to be related to improper use of the lens shield. Salvage re-RT was successful. The 10-year actuarial relapse-free survival, cause-specific survival, and overall survival rates were 93.1%, 97.9%, and 86.9%, respectively. Conclusion: Most of the MALT lymphoma of the orbit was localized at diagnosis and extraorbital relapse rarely occurred. Therefore, extensive staging workup at the time of diagnosis and follow-up studies to detect distant relapse may not be obligatory. Low-dose RT alone with proper lens shielding is the optimum treatment modality for orbital MALT lymphoma.

Original languageEnglish
Pages (from-to)228-233
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume65
Issue number1
DOIs
Publication statusPublished - 2006 May 1

Fingerprint

Marginal Zone B-Cell Lymphoma
radiation therapy
Radiotherapy
orbitals
Recurrence
bone marrow
lesions
Lenses
Bone Marrow
lenses
dosage
Survival
shielding
regression analysis
grade
Lymphoma
Survival Rate
Radiation
orbits
Biopsy

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Suh, Chang-Ok ; Shim, Su Jung ; Lee, Sang wook ; Yang, Woo Ick ; Lee, Sang Yeul ; Hahn, Jee Sook. / Orbital marginal zone B-cell lymphoma of MALT : Radiotherapy results and clinical behavior. In: International Journal of Radiation Oncology Biology Physics. 2006 ; Vol. 65, No. 1. pp. 228-233.
@article{87d388ffad6a402f8d0fdd15275ea487,
title = "Orbital marginal zone B-cell lymphoma of MALT: Radiotherapy results and clinical behavior",
abstract = "Purpose: To elucidate the clinical behavior and treatment outcome of low-grade primary orbital lymphoma arising from mucosa-associated lymphoid tissue (MALT). Methods and Materials: Forty-eight patients with pathologically confirmed marginal zone B-cell lymphoma of MALT were treated with radiotherapy (RT). Thirty-eight patients (79.1{\%}) received thorough staging workup studies including bone marrow biopsy. Radiation doses ranged from 5.4 to 30.6 Gy (median, 30.6 Gy). Median follow-up period was 70 months. Results: Only 2 patients revealed extraorbital lymphoma involvement (bone marrow, skin). Forty-six of 52 eye lesions showed complete response to RT. Six lesions demonstrated a partial response and showed gradual regression during the follow-up period of 39-72 months. Three patients experienced local recurrences at 34, 48, and 52 months after RT, which seemed to be related to improper use of the lens shield. Salvage re-RT was successful. The 10-year actuarial relapse-free survival, cause-specific survival, and overall survival rates were 93.1{\%}, 97.9{\%}, and 86.9{\%}, respectively. Conclusion: Most of the MALT lymphoma of the orbit was localized at diagnosis and extraorbital relapse rarely occurred. Therefore, extensive staging workup at the time of diagnosis and follow-up studies to detect distant relapse may not be obligatory. Low-dose RT alone with proper lens shielding is the optimum treatment modality for orbital MALT lymphoma.",
author = "Chang-Ok Suh and Shim, {Su Jung} and Lee, {Sang wook} and Yang, {Woo Ick} and Lee, {Sang Yeul} and Hahn, {Jee Sook}",
year = "2006",
month = "5",
day = "1",
doi = "10.1016/j.ijrobp.2005.11.035",
language = "English",
volume = "65",
pages = "228--233",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

Orbital marginal zone B-cell lymphoma of MALT : Radiotherapy results and clinical behavior. / Suh, Chang-Ok; Shim, Su Jung; Lee, Sang wook; Yang, Woo Ick; Lee, Sang Yeul; Hahn, Jee Sook.

In: International Journal of Radiation Oncology Biology Physics, Vol. 65, No. 1, 01.05.2006, p. 228-233.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Orbital marginal zone B-cell lymphoma of MALT

T2 - Radiotherapy results and clinical behavior

AU - Suh, Chang-Ok

AU - Shim, Su Jung

AU - Lee, Sang wook

AU - Yang, Woo Ick

AU - Lee, Sang Yeul

AU - Hahn, Jee Sook

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Purpose: To elucidate the clinical behavior and treatment outcome of low-grade primary orbital lymphoma arising from mucosa-associated lymphoid tissue (MALT). Methods and Materials: Forty-eight patients with pathologically confirmed marginal zone B-cell lymphoma of MALT were treated with radiotherapy (RT). Thirty-eight patients (79.1%) received thorough staging workup studies including bone marrow biopsy. Radiation doses ranged from 5.4 to 30.6 Gy (median, 30.6 Gy). Median follow-up period was 70 months. Results: Only 2 patients revealed extraorbital lymphoma involvement (bone marrow, skin). Forty-six of 52 eye lesions showed complete response to RT. Six lesions demonstrated a partial response and showed gradual regression during the follow-up period of 39-72 months. Three patients experienced local recurrences at 34, 48, and 52 months after RT, which seemed to be related to improper use of the lens shield. Salvage re-RT was successful. The 10-year actuarial relapse-free survival, cause-specific survival, and overall survival rates were 93.1%, 97.9%, and 86.9%, respectively. Conclusion: Most of the MALT lymphoma of the orbit was localized at diagnosis and extraorbital relapse rarely occurred. Therefore, extensive staging workup at the time of diagnosis and follow-up studies to detect distant relapse may not be obligatory. Low-dose RT alone with proper lens shielding is the optimum treatment modality for orbital MALT lymphoma.

AB - Purpose: To elucidate the clinical behavior and treatment outcome of low-grade primary orbital lymphoma arising from mucosa-associated lymphoid tissue (MALT). Methods and Materials: Forty-eight patients with pathologically confirmed marginal zone B-cell lymphoma of MALT were treated with radiotherapy (RT). Thirty-eight patients (79.1%) received thorough staging workup studies including bone marrow biopsy. Radiation doses ranged from 5.4 to 30.6 Gy (median, 30.6 Gy). Median follow-up period was 70 months. Results: Only 2 patients revealed extraorbital lymphoma involvement (bone marrow, skin). Forty-six of 52 eye lesions showed complete response to RT. Six lesions demonstrated a partial response and showed gradual regression during the follow-up period of 39-72 months. Three patients experienced local recurrences at 34, 48, and 52 months after RT, which seemed to be related to improper use of the lens shield. Salvage re-RT was successful. The 10-year actuarial relapse-free survival, cause-specific survival, and overall survival rates were 93.1%, 97.9%, and 86.9%, respectively. Conclusion: Most of the MALT lymphoma of the orbit was localized at diagnosis and extraorbital relapse rarely occurred. Therefore, extensive staging workup at the time of diagnosis and follow-up studies to detect distant relapse may not be obligatory. Low-dose RT alone with proper lens shielding is the optimum treatment modality for orbital MALT lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=33646001091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646001091&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2005.11.035

DO - 10.1016/j.ijrobp.2005.11.035

M3 - Article

C2 - 16503386

AN - SCOPUS:33646001091

VL - 65

SP - 228

EP - 233

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -